Brookfield Corp’s Amicus Therapeutics FOLD Stock Holding History

Brookfield Corp’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-111,751	Closed	-$1.17M	–	643
2022 Q3	$1.17M	Sell	111,751 -403,249	-78%	-$4.49M	﹤0.01%	521
2022 Q2	$5.53M	Sell	515,000 -95,000	-16%	-$782K	0.02%	233
2022 Q1	$5.78M	Sell	610,000 -190,000	-24%	-$1.78M	0.02%	234
2021 Q4	$9.24M	Sell	800,000 -45,000	-5%	-$502K	0.04%	133
2021 Q3	$8.07M	Buy	845,000 +350,822	+71%	+$3.59M	0.03%	158
2021 Q2	$4.76M	Buy	494,178 +14,500	+3%	+$142K	0.02%	226
2021 Q1	$4.74M	Buy	+479,678	New	+$7.42M	0.02%	170

Other funds holding FOLD

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Brookfield Corp's FOLD Position: Q4 2022 in Review

Brookfield Corp sold out of Amicus Therapeutics (FOLD) in Q4 2022, closing a stake of 111,751 shares — an estimated $1.17M sold.

Brookfield Corp first reported a position in FOLD in Q1 2021 and held it in 7 quarters. The position peaked at $9.24M in Q4 2021. 230 funds tracked by Wall St. Rank hold FOLD as of Q4 2022.

Brookfield Corp reported no remaining Amicus Therapeutics position as of Q4 2022 after selling out during the quarter.
Brookfield Corp sold 111,751 Amicus Therapeutics shares in Q4 2022, an estimated $1.17M.
Brookfield Corp first reported a position in Amicus Therapeutics in Q1 2021 and held it in 7 quarters.
Brookfield Corp's Amicus Therapeutics position peaked at $9.24M in Q4 2021.
230 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2022.

Based on Brookfield Corp's 13F filing for Q4 2022, filed 14 Feb 2023.